Serge Saxonov - 22 Mar 2022 Form 4 Insider Report for 10x Genomics, Inc. (TXG)

Role: Chief Executive Officer, Director
Signature: /s/ Eric S. Whitaker, as Attorney-in-Fact for Serge Saxonov
Issuer symbol: TXG
Transactions as of: 22 Mar 2022
Net transactions value: $0
Form type: 4
Filing time: 24 Mar 2022, 17:12:58 UTC
Previous filing: 24 Feb 2022
Next filing: 25 May 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TXG	Class A Common Stock	Award	$0	+58,731	+6.4%	$0.000000	971,473	22 Mar 2022	Direct	F1
holding	TXG	Class A Common Stock						4,138	22 Mar 2022	See footnote	F2
holding	TXG	Class A Common Stock						89,960	22 Mar 2022	See footnote	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TXG	Stock Option (Right to Buy)	Award	$0	+146,827		$0.000000	146,827	22 Mar 2022	Class A Common Stock	146,827	$69.56	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock. One-sixteenth of the RSUs shall vest on May 21, 2022 and on each three-month anniversary thereafter, subject to the Reporting Person continuing as a service provider through each such date.
F2	The shares are held by the Andromeda Trust, for which the Reporting Person serves as trustee.
F3	The shares are held by the Y/S Descendants' Trust, for which the Reporting Person serves as trustee.
F4	This option, granted pursuant to the Issuer's 2019 Omnibus Incentive Plan, vests as to one forty-eighth of the shares on May 1, 2022 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.